Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

202 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical significance of CXC chemokine receptor-4 and c-Met in childhood rhabdomyosarcoma.
Diomedi-Camassei F, McDowell HP, De Ioris MA, Uccini S, Altavista P, Raschellà G, Vitali R, Mannarino O, De Sio L, Cozzi DA, Donfrancesco A, Inserra A, Callea F, Dominici C. Diomedi-Camassei F, et al. Among authors: dominici c. Clin Cancer Res. 2008 Jul 1;14(13):4119-27. doi: 10.1158/1078-0432.CCR-07-4446. Clin Cancer Res. 2008. PMID: 18593989
Malignant pancreatic endocrine tumor in a child with tuberous sclerosis.
Francalanci P, Diomedi-Camassei F, Purificato C, Santorelli FM, Giannotti A, Dominici C, Inserra A, Boldrini R. Francalanci P, et al. Among authors: dominici c. Am J Surg Pathol. 2003 Oct;27(10):1386-9. doi: 10.1097/00000478-200310000-00012. Am J Surg Pathol. 2003. PMID: 14508401
Clinical and molecular evidence for c-kit receptor as a therapeutic target in neuroblastic tumors.
Uccini S, Mannarino O, McDowell HP, Pauser U, Vitali R, Natali PG, Altavista P, Andreano T, Coco S, Boldrini R, Bosco S, Clerico A, Cozzi D, Donfrancesco A, Inserra A, Kokai G, Losty PD, Nicotra MR, Raschellà G, Tonini GP, Dominici C. Uccini S, et al. Among authors: dominici c. Clin Cancer Res. 2005 Jan 1;11(1):380-9. Clin Cancer Res. 2005. PMID: 15671569
High histologic and overall response to dose intensification of ifosfamide, carboplatin, and etoposide with cyclophosphamide, doxorubicin, and vincristine in patients with high-risk Ewing sarcoma family tumors: the Bambino Gesù Children's Hospital experience.
Milano GM, Cozza R, Ilari I, De Sio L, Boldrini R, Jenkner A, De Ioris M, Inserra A, Dominici C, Donfrancesco A. Milano GM, et al. Among authors: dominici c. Cancer. 2006 Apr 15;106(8):1838-45. doi: 10.1002/cncr.21780. Cancer. 2006. PMID: 16532434 Free article. Clinical Trial.
Ifosfamide/carboplatin/etoposide (ICE) as front-line, topotecan/cyclophosphamide as second-line and oral temozolomide as third-line treatment for advanced neuroblastoma over one year of age.
Donfrancesco A, Jenkner A, Castellano A, Ilari I, Milano GM, De Sio L, Cozza R, Fidani P, Deb G, De Laurentis C, Inserra A, Dominici C. Donfrancesco A, et al. Among authors: dominici c. Acta Paediatr Suppl. 2004 May;93(445):6-11. doi: 10.1111/j.1651-2227.2004.tb03048.x. Acta Paediatr Suppl. 2004. PMID: 15176712 Clinical Trial.
Temozolomide in resistant or relapsed pediatric solid tumors.
De Sio L, Milano GM, Castellano A, Jenkner A, Fidani P, Dominici C, Donfrancesco A. De Sio L, et al. Among authors: dominici c. Pediatr Blood Cancer. 2006 Jul;47(1):30-6. doi: 10.1002/pbc.20516. Pediatr Blood Cancer. 2006. PMID: 16047361 Clinical Trial.
202 results